INVEX Therapeutics Ltd (IXC)
Australian Securities Exchange · Australia · prices in AUD · close of 20 Oct 2026
Key indicators
| Last close | AUD 0.105 |
|---|---|
| 52-week range | 0.090 – 0.150 |
| Return, 1 month / 3 months | −8.7% / −12.5% |
| Return, 1 year / 3 years | +0.0% / −50.0% |
| Trend | Below its 200-day average |
| RSI (14) | 41 |
| Volatility (1 year) | 86.8% |
| Worst drawdown (1 year) | -37.9% |
| Average daily value traded | 0.00M AUD |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
Summary
INVEX Therapeutics Ltd (IXC) trades on the Australian Securities Exchange in Australia. It last closed at AUD 0.105 on 20 October 2026.
Its price-based Market X-Ray is 53 out of 100 (a fair price profile), ranking 839 of 1,815 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 0.0% and over the last three months it fell 12.5%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Australian Securities Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 66 · Fair | Mixed trend against its averages. | |
| Above 200-day average | -6.8% | ||
| From 52-week high | -27.6% | ||
| Momentum | 64 · Fair | Typical recent returns for this exchange. | |
| 3-month return | -12.5% | ||
| 6-month return | 5.0% | ||
| 12-month return, skipping the last month | 9.5% | ||
| Stability (higher is calmer) | 56 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 86.8% | ||
| Worst drawdown, 1 year (smaller is calmer) | -37.9% | ||
| Liquidity | 9 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.00M AUD | ||
| Zero-volume days | 55.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 1 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | +0.0% |
|---|---|
| 1 month | −8.7% |
| 3 months | −12.5% |
| 6 months | +5.0% |
| 1 year | +0.0% |
| 3 years | −50.0% |
| 5 years | −84.7% |
Signals
| 50-day / 200-day average | 0.113 / 0.113 |
|---|---|
| Golden / death cross (60 days) | Death, 0 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.002 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 8 Dec 2023 | AUD 0.1863 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Australian Securities Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.